These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31688023)

  • 1. Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
    Rezaie A; Heimanson Z; McCallum R; Pimentel M
    Am J Gastroenterol; 2019 Dec; 114(12):1886-1893. PubMed ID: 31688023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
    Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
    Bae S; Lee KJ; Kim YS; Kim KN
    J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.
    Collins BS; Lin HC
    J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):382-6. PubMed ID: 21240023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Rao SSC; Heimanson Z; Pimentel M
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
    Zhuang X; Tian Z; Luo M; Xiong L
    BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome.
    Boltin D; Perets TT; Shporn E; Aizic S; Levy S; Niv Y; Dickman R
    Ann Clin Microbiol Antimicrob; 2014 Oct; 13():49. PubMed ID: 25319626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls.
    Bratten JR; Spanier J; Jones MP
    Am J Gastroenterol; 2008 Apr; 103(4):958-63. PubMed ID: 18371134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
    Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
    Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
    Meyrat P; Safroneeva E; Schoepfer AM
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome.
    Youn YH; Park JS; Jahng JH; Lim HC; Kim JH; Pimentel M; Park H; Lee SI
    Dig Dis Sci; 2011 Jul; 56(7):2059-66. PubMed ID: 21240630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
    Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical value of breath ammonia determination in patients with irritable bowel syndrome.
    Chojnacki C; Błońska A; Mędrek-Socha M; Chojnacki M; Konrad P
    Pol Merkur Lekarski; 2022 Dec; 50(300):360-363. PubMed ID: 36645681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between symptoms of irritable bowel syndrome and methane and hydrogen on lactulose breath test.
    Lee KN; Lee OY; Koh DH; Sohn W; Lee SP; Jun DW; Lee HL; Yoon BC; Choi HS; Hahm JS
    J Korean Med Sci; 2013 Jun; 28(6):901-7. PubMed ID: 23772156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Usefulness of lactulose breath test for the prediction of small intestinal bacterial overgrowth in irritable bowel syndrome].
    Park JS; Yu JH; Lim HC; Kim JH; Yoon YH; Park HJ; Lee SI
    Korean J Gastroenterol; 2010 Oct; 56(4):242-8. PubMed ID: 20962560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.
    Weinstock LB; Geng B; Brandes SB
    Can J Urol; 2011 Aug; 18(4):5826-30. PubMed ID: 21854715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS.
    Law D; Pimentel M
    Dig Dis Sci; 2010 Aug; 55(8):2302-8. PubMed ID: 19834807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.
    Fodor AA; Pimentel M; Chey WD; Lembo A; Golden PL; Israel RJ; Carroll IM
    Gut Microbes; 2019; 10(1):22-33. PubMed ID: 29708822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.